Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues.
about
Nanoparticle-mediated drug delivery for treating melanomaPolymer-drug conjugates: origins, progress to date and future directionsCancer nanotechnology: emerging role of gold nanoconjugatesPolymer nanostructures synthesized by controlled living polymerization for tumor-targeted drug deliveryPoly[N-(2-hydroxypropyl)methacrylamide] polymers diffuse in brain extracellular space with same tortuosity as small molecules.Nanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A ReviewA systems approach for tumor pharmacokineticsMacromolecule extravasation-xenograft size matters: a systematic study using probe-based confocal laser endomicroscopy (pCLE)Superparamagnetic iron oxide nanoparticles stabilized by a poly(amidoamine)-rhenium complex as potential theranostic probe.Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma.Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers.Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation.Investigations on surface modified dendrimers: enzymatic hydrolysis and uptake into MCF-7 breast cancer cells.Emerging PEGylated drugs.HPMA copolymers: origins, early developments, present, and future.Trastuzumab-conjugated liposome-coated fluorescent magnetic nanoparticles to target breast cancer.Macromolecular therapeuticsRefilling drug delivery depots through the blood.Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents.Hydroxyethyl starch as an effective methotrexate carrier in anticancer therapy.Significance and applications of nanoparticles in siRNA delivery for cancer therapy.New strategies for polymer development in pharmaceutical science--a short review.Quantitating antibody uptake in vivo: conditional dependence on antigen expression levels.Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.Improving chemoradiotherapy with nanoparticle therapeutics.Recent progress in drug delivery systems for anticancer agents.Macrophage-targeted photodynamic therapy.Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: A synergistic combination nanotherapy for ovarian cancer treatment.Doxorubicin-incorporated polymeric micelles composed of dextran-b-poly(DL-lactide-co-glycolide) copolymer.Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates.Improved systemic pharmacokinetics, biodistribution, and antitumor activity of CpG oligodeoxynucleotides complexed to endogenous antibodies in vivo.Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting.Smart polymeric carriers for enhanced intracellular delivery of therapeutic macromolecules.Tumour targeting: biological factors and formulation advances in injectable lipid nanoparticles.Biological rationale for the design of polymeric anti-cancer nanomedicines.Targeting of multidrug-resistant human ovarian carcinoma cells with anti-P-glycoprotein antibody conjugates.Micro-CT enables microlocalisation and quantification of Her2-targeted gold nanoparticles within tumour regionsA combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)Block copolymer micelles as delivery vehicles of hydrophobic drugs: micelle-cell interactions.
P2860
Q26798379-9FA82492-08A0-405E-A57C-323E6D9269CAQ27002505-777FC293-6118-4143-8B88-467E1F14F231Q27021820-58180BE1-7C6C-4533-88CE-BA287D3B5AF9Q28085664-4ECF2133-B459-46F6-AB09-6F2122B8100DQ28346261-7EC559AC-8208-4FC3-8D09-A9DAFFE9E098Q28394719-00FEC176-2D77-42E1-929D-EC46218EBF86Q28477077-8DAEE1EE-2C4D-4850-964C-4F3340CC495CQ30557217-DD91B2C6-9222-484F-8E36-89DD8C992BBDQ30685707-C8F04846-1015-4717-9548-88030C5D997FQ30886810-9A5B6528-3830-404F-B23C-013504048EB1Q33235069-68B47793-40E0-479B-9AFA-78A17B0AC9D1Q33292829-8396F85F-152A-411E-833E-8E812EF3F8AEQ33315131-51F3056A-0087-41F1-8773-CC62F34BE05FQ33447691-FD6323F6-5FE3-4230-8F1B-7ED9743D3FFCQ33719148-83A8DF9A-5AA5-4FA8-B815-FAAB72BFB724Q33929273-7D3C2930-20C6-48F5-873E-79849D8B30A5Q34079574-1B897DCA-523B-4D95-A81D-2B7BE6262813Q34144515-DEED9426-B714-45CA-BA3D-F61AD2C8B564Q34265621-5C4AAEDA-1447-47E9-A08A-3FC78B652FACQ34292505-38C91CA6-C7BC-4191-97DC-A2E74B759A2AQ34297263-C9B62B65-3E2C-4259-9FC2-C91FF380DEF4Q34385681-2B86D4BD-C09F-4F9F-A615-B3B281A6BE5EQ34400470-5A48B79B-0778-4318-910F-0F580B9DE259Q34447986-158C10B9-5D5A-4479-BCC7-B2F446BB6B55Q34564219-F5CC3C27-FCE3-460F-BA34-B5A60FC22D96Q34756263-6072E08E-E371-4926-8F46-03C8A5EB8D66Q34763443-87DF18C2-97B0-4CDB-A622-7744A2D9BED5Q35032561-ED346B8A-8377-48D0-99A9-D4458B1930FCQ35122756-BC1D0766-3495-4E0D-87B0-92CCBADD704DQ35227265-295A1587-A7F3-4C60-8AE0-80E43BBD57DDQ35990439-C6D518B5-5C88-4947-93B4-0A65E1058BD3Q36001530-9C72B418-3D38-4826-B622-3EEBDE6A47B2Q36040794-FE91A60D-52A8-4E23-8AC6-E699B309B15DQ36098273-F92A42CA-0180-4D8A-B556-39184556995AQ36160333-A44A3D18-CB66-436B-B452-60B5EC0377C6Q36185372-67E527C7-DEE6-4F70-8A4B-FEDA162FFD72Q36324571-5FDB6A5B-1664-4671-97EF-2F985416CB8AQ36462972-6AB83005-168C-4211-867A-4425C0F03C4BQ36643541-472B46D8-D4E5-4223-A22E-8463CEC63573Q36648447-B8D52A75-2EC8-427F-A730-6EC7B3A13D5D
P2860
Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Early phase tumor accumulation ...... ween tumor and normal tissues.
@en
Early phase tumor accumulation ...... ween tumor and normal tissues.
@nl
type
label
Early phase tumor accumulation ...... ween tumor and normal tissues.
@en
Early phase tumor accumulation ...... ween tumor and normal tissues.
@nl
prefLabel
Early phase tumor accumulation ...... ween tumor and normal tissues.
@en
Early phase tumor accumulation ...... ween tumor and normal tissues.
@nl
P2093
P2860
P1476
Early phase tumor accumulation ...... ween tumor and normal tissues.
@en
P2093
J Strohalm
P2860
P304
P356
10.1111/J.1349-7006.1998.TB00563.X
P577
1998-03-01T00:00:00Z